Why Medication Alone Fails MOUD Patients After Release
Introduction
Medication for Opioid Use Disorder (MOUD) is one of the most powerful tools in modern addiction treatment. Medications such as buprenorphine save lives, reduce overdose risk, and improve long-term stability. However, outcomes depend not just on whether medication is used, but how it is used. Two common failures continue to undermine otherwise well-intentioned programs: treating medication as a stand-alone solution without supportive care, and abruptly stopping MOUD at release from jail or prison.
At DevotedDOc, we treat opioid use disorder (OUD) as a chronic medical condition that requires continuity and clinical oversight. This article explains why medication alone is not enough, why discontinuing MOUD at release causes harm, and what evidence-based systems do differently to support recovery and reduce overdose deaths. [1][2]
MOUD Works But Only When Used Correctly
Decades of research confirm that MOUD reduces illicit opioid use, overdose mortality, and all-cause death. Buprenorphine, in particular, is recognized as a gold-standard treatment for OUD. However, no major medical authority recommends medication in isolation or abrupt discontinuation after stabilization. Outcomes worsen when MOUD is treated as a temporary intervention instead of ongoing medical care. [2][3]
Why Medication Alone Isn’t Enough
1. OUD Is a Chronic, Relapsing Medical Condition
Opioid use disorder alters brain chemistry, stress response, and impulse regulation. Medication stabilizes these systems, but it does not erase the social, psychological, and environmental factors that influence relapse. Without ongoing clinical monitoring and support, patients remain vulnerable especially during periods of stress or transition. [3][4]
Effective care pairs medication with medical follow-up, education, and access to supportive services.
2. Behavioral and Social Stressors Persist After Stabilization
Housing insecurity, unemployment, legal obligations, and family reintegration challenges do not disappear when medication starts. If these stressors are not addressed alongside MOUD, relapse risk increases. Medication reduces cravings, but it does not remove external pressures that drive substance use. [4][5]
This is especially relevant for justice-involved individuals navigating reentry.
3. Lack of Follow-Up Leads to Dropout and Relapse
Patients who receive medication without structured follow-up are more likely to disengage from care. Missed appointments, unmanaged side effects, and lack of dose adjustments contribute to treatment dropout. Evidence shows that retention in care not just medication initiation is one of the strongest predictors of positive outcomes. [2][6]
Why Stopping MOUD at Release Is Especially Dangerous
1. Opioid Tolerance Drops During Incarceration
During incarceration, individuals are typically cut off from illicit opioids. As a result, tolerance decreases rapidly. When MOUD is stopped at release and relapse occurs, previously tolerated doses can become fatal. This is a primary driver of post-release overdose deaths. [7][8]
Stopping medication removes a critical protective factor at the most dangerous moment.
2. Abrupt Discontinuation Increases Cravings and Withdrawal
Buprenorphine suppresses cravings and withdrawal symptoms. When it is suddenly discontinued, these symptoms return often intensely. This physiological rebound pushes individuals toward illicit opioid use, increasing overdose risk. [1][7]
From a medical standpoint, abrupt discontinuation contradicts best practices for managing any chronic disease.
3. The First Weeks After Release Carry Extreme Risk
People leaving incarceration are 10 to 40 times more likely to die from an opioid overdose than the general population. The first two weeks post-release are the most dangerous, with mortality risk exceeding 100 times baseline levels. Discontinuing MOUD during this window dramatically increases preventable deaths. [8][9]
The Myth of “Short-Term MAT”
Some programs still view MOUD as a temporary bridge rather than ongoing care. This approach is not supported by evidence. Short-term or tapered MOUD is associated with higher relapse and overdose rates compared to maintenance treatment. There is no fixed timeline for MOUD duration should be determined clinically, not administratively. [3][6]
What Evidence-Based Programs Do Instead
1. Treat MOUD as Ongoing Medical Care
High-performing programs manage MOUD the same way they manage other chronic conditions. Clinicians continue medication as long as it provides benefit, with regular reassessment rather than arbitrary time limits.[2][4]
2. Integrate Medication With Clinical Oversight
Clinicians pair medication with regular physician follow-up, patient education, and monitoring for co-occurring conditions. At the same time, care teams offer counseling and support services alongside medication rather than using them as gatekeeping requirements. [5][6]
3. Plan for Continuity Before Release
Reentry planning begins well before release. This includes confirming medication access, scheduling follow-up appointments, and addressing insurance or logistical barriers. Programs that plan early see significantly better post-release engagement. [1][9]
4. Use Telemedicine to Prevent Gaps
Telemedicine plays a critical role in preventing treatment interruption. Tele-MOUD allows patients to continue seeing licensed physicians immediately after release, even if they lack transportation or stable housing. Continuity is preserved during the highest-risk period. [6][10]
Common Justifications for Stopping MOUD and Why They Fail
“They’re Stable Now”
Stability on MOUD is evidence the medication is working, not a reason to stop it. [3][4]
“They Need to Be Drug-Free”
MOUD is evidence-based treatment, not drug substitution. Outcomes improve when medication continues. [2][5]
“We Don’t Have Community Follow-Up”
Lack of follow-up is a system failure, not a clinical rationale. Telemedicine addresses this barrier directly. [6][10]
The Role of Telemedicine in Doing It Right
Telemedicine enables continuity, flexibility, and access that traditional models cannot always provide. By allowing physician-led care to continue across custody and reentry, tele-MOUD prevents the most dangerous gaps in treatment. For many systems, telemedicine is the difference between theoretical access and real-world continuity. [6][10]
How DevotedDOc Approaches MOUD Continuity
DevotedDOc provides physician-led, telemedicine-based addiction treatment designed to avoid the failures outlined above. Our approach emphasizes:
- Ongoing buprenorphine-based MOUD
- Licensed physician oversight
- Regular follow-up and dose management
- Continuity through incarceration and reentry
- Stigma-free, medically grounded care
We focus on long-term outcomes, not short-term checkboxes.
Institutional and Public Health Impact
Programs that maintain MOUD through reentry see:
- Lower overdose mortality
- Improved treatment retention
- Reduced emergency healthcare utilization
- Lower recidivism rates
Stopping medication undermines these gains and increases downstream costs for healthcare and justice systems alike. [7][8][9]
Conclusion
Medication alone is not enough but stopping medication is far worse. MOUD saves lives when clinicians deliver it as part of continuous, medically supervised care. Abrupt discontinuation at release strips away protection at the most dangerous moment, leading to preventable overdose deaths and failed reentry.
Evidence-based systems do not ask when to stop MOUD; instead, they focus on supporting patients safely for as long as treatment is needed. [1][3][6]
Call to Action: Partner or Refer
For facilities and organizations: DevotedDOc supports correctional systems, courts, re-entry nonprofits, and public health stakeholders with physician-led MOUD models and scalable continuity workflows.
For families and supporters: If you want to help someone start treatment, you can support access directly through DevotedDOc’s donation pathway:
https://devoteddoc.com/donate/
References
- National Sheriff’s Association. Jail-Based Medication-Assisted Treatment.
- Substance Abuse and Mental Health Services Administration (SAMHSA). Breaking the Cycle: MAT in the Criminal Justice System.
- National Institute on Drug Abuse (NIDA). Effective Treatments for Opioid Addiction.
- World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence.
- National Council for Mental Wellbeing. MAT for OUD in Jails and Prisons Toolkit.
- SAMHSA. Telehealth for the Treatment of Substance Use Disorders.
- American Civil Liberties Union. Over-Jailed and Un-Treated.
- Addiction Science & Clinical Practice. Post-Release Opioid-Related Overdose Risk.
- JAMA Network Open. Trends in Buprenorphine Use in U.S. Jails and Prisons.
- NIDA. Telehealth and Opioid Use Disorder Treatment.
Medically Reviewed By:
